|
YUHAN is a pharmaceutical company founded in 1926 that manufactures and sells prescription drugs, over-the-counter medicines, animal health products, and consumer goods. Its business segments include pharmaceuticals, healthcare, and overseas operations. Key products include the non-small cell lung cancer drug Leqrazza (lazertinib), Antipyrine, Picom C, Duowell, and Kopu Syrup. The company develops active pharmaceutical ingredients (APIs) for HIV and HCV treatments, supplying global partners such as Gilead Sciences. YUHAN also holds license-out agreements with partners like Janssen Biotech and Berlinger Ingelheim for oncology and metabolic disease candidates. The company operates subsidiaries including Yuhan Medica, Wise Med, Yuhan Health Life, and Ad Pharma. It serves domestic and international markets, with a focus on expanding its global presence through API exports and finished drug distribution. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage yuhan.co.kr |
| Sector Healthcare | IR page — | |
|
Tags
oncology, active pharmaceutical ingredients, animal health, consumer goods, respiratory diseases, metabolic diseases, license-out, innovative drugs, generic drugs, Leqrazza, lazertinib, Antipyrine, Picom C, Duowell, Kopu Syrup, Elena, Rosuvamiv, Atovamiv, Yuhan Medica, Wise Med, Yuhan Health Life, Ad Pharma, Yuhan Chemical, Yuhan Kimberly, Yuhan SmithKline, Yuhan SP, Yuhan Cyanamide, Yuhan Corax, YH14618, YH25448, YH25724, YH12852, YH42946, YH35995, Lesigercept, Nesfrotamig, YH32364, AD-209, AD-214, AD-216, AD-217, AD-218, AD-223, AD-224, AD-2303, AD-2304, AD-114, NTCB-01/02, YHP2401, AD-211, AD-230, AD-116, AD-232, AD-113, AD-109, AD-115, AD-229
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 5.876T |
| Market cap (USD) | $ 4.325B |
| P/E | 22.89 |
| PEG | 0.85 |
| P/BV | 2.46 |
| P/S | 2.57 |
| P/OCF | 35.47 |
| P/FCF | 218.03 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 8.6% |
| ROI | 8.2% |
| ROIC | 3.7% |
| Profit margin | 8.9% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 26.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 35.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.187T | 2.068T | 1.859T | 1.776T | 1.688T | 1.62T | 1.48T | 1.519T | 1.462T | 1.321T | 1.129T | 1.017T | 943.609B |
| Net profit | 194.079B | 70.687B | 136.089B | 95.144B | 102.583B | 190.402B | 36.612B | 58.335B | 109.637B | 161.249B | 126.047B | 90.948B | 86.461B |
| Free cash flow | 6.626B | -62.477B | -17.352B | 41.234B | 52.849B | -22.623B | 23.222B | 47.45B | 69.353B | -5.932B | 44.973B | 58.547B | 24.017B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 236B | 284B | 343B | 397B | 443B | 461B | 497B | 559B | 609B | 694B |
| ↳ YoY growth | +10.0% | +20.4% | +21.0% | +15.7% | +11.5% | +4.2% | +7.7% | +12.5% | +9.0% | +14.0% |
| ↳ 5y CAGR | +15.6% | +14.4% | +11.9% | +10.2% | +8.9% | +9.4% | ||||
| Other receivables (KRW) | — | — | — | — | — | 12.8B | 12.4B | 15B | 17B | 19.5B |
| Borrowings, current (KRW) | 51.1B | 3.19B | 1.3B | 15B | 48.5B | 20.5B | 64.1B | 4.15B | 0.00 | — |
| Borrowings, non-current (KRW) | 140B | 115B | 70.2B | 44.3B | 46.8B | 28.1B | 625M | 60.2B | 105B | 71.1B |
| Bonds payable (KRW) | — | — | — | — | — | — | 364M | 0.00 | 0.00 | — |
| Cash and deposits (KRW) | 245B | 257B | 241B | 274B | 353B | 254B | 293B | 299B | 306B | 349B |
| Intangible assets (KRW) | 15.9B | — | — | — | — | 87.6B | 138B | 298B | 285B | 300B |
| Net debt (borrowings + leases - cash) (KRW) | -105B | -138B | -170B | -215B | -258B | -205B | -228B | -235B | -201B | -277B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 74.1B | 126B | 93.5B | 66B | 28.8B | 99B | 99.5B | 144B | 54.6B | 106B |
| Purchases of property, plant and equipment (KRW) | -80.1B | -56.8B | -46B | -42.8B | -51.5B | -46.2B | -58.3B | -161B | -117B | -99.6B |
| Purchases of intangible assets (KRW) | -4.55B | -3.14B | -2.59B | -3.97B | -39.7B | -35.7B | -36.1B | -42.6B | -16.8B | -34.9B |
| Change in receivables (cash effect) (KRW) | -21.4B | -55.6B | -59.5B | -55.4B | -61.2B | 8.61B | -1.37B | 3.42B | -1.98B | 422M |
| Change in inventories (cash effect) (KRW) | -68.3B | 40.7B | 23.4B | 56.5B | -69.3B | -26.1B | -382M | -5.4B | -58.6B | -33.5B |
| Change in payables (cash effect) (KRW) | -10.2B | -45.7B | -7.7B | 21.3B | 11.8B | 20.6B | -7.81B | 44.5B | -4.36B | -310M |
| Dividends paid (cash effect) (KRW) | -20.5B | -20.5B | -21.7B | -22.7B | -23.8B | -24.9B | -26.1B | -27.3B | -32.1B | -37.5B |
| Share buybacks (cash effect) (KRW) | -1.16B | -1.06B | -12.3B | -8.4B | -3.12B | -16.4B | -16.5B | -7.46B | -2.51B | -20B |
| Interest paid (cash effect) (KRW) | -5.37B | -5.44B | -5.95B | -3.1B | -2.48B | -2.71B | -3.11B | -4.3B | -12.1B | -11.7B |
| Income taxes paid (cash effect) (KRW) | -35B | -37.6B | -37.7B | -35.6B | -28B | -39.2B | -66.2B | -32.9B | -27.3B | -26.5B |
| Share-based compensation (KRW) | — | — | — | — | — | 689M | 464M | 339M | 1.31B | 788M |
| Operating cash flow before change in receivables (KRW) | 95.5B | 182B | 153B | 121B | 90B | 90.4B | 101B | 141B | 56.6B | 106B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -10.5B | 66.2B | 44.9B | 19.3B | -62.3B | 17.1B | 5.15B | -59.9B | -79.3B | -28.2B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 154B | 106B | 79.5B | 32.8B | 213B | 124B | 91.7B | 118B | 53.8B | 234B |
| Comprehensive income to owners (KRW) | — | — | — | — | — | 127B | 96.5B | 120B | 69.8B | 243B |
| Provision for credit losses (KRW) | — | -2.9B | 811M | 351M | 1.19B | -1.42B | 2.08B | 1.33B | -145M | 2.58B |
| Credit cost ratio (credit losses / average receivables) (%) | — | 1.1% | 0.3% | 0.1% | 0.3% | 0.3% | 0.4% | 0.2% | 0.0% | 0.4% |
| Reported | Apr 2, 2018 | Apr 2, 2018 | Apr 1, 2019 | Mar 30, 2020 | Mar 11, 2021 | Mar 7, 2024 | Mar 12, 2025 | Mar 12, 2025 | Mar 12, 2025 | Mar 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding YUHAN
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DGRE | 0.49% | 16,032 | $ 726.423K | Jun 30, 2026 |
| AVEE | 0.34% | 7,382 | $ 443.209K | Nov 16, 2026 |
| DFEV | 0.08% | 28,492 | $ 1.709M | Nov 12, 2026 |
| DFSE | 0.04% | 3,955 | $ 237.22K | Nov 12, 2026 |
| NTSE | 0.02% | 248 | $ 11.237K | Jun 30, 2026 |
| DFEM | 0.02% | 28,414 | $ 1.704M | Nov 12, 2026 |
| DFAE | 0.02% | 26,740 | $ 1.604M | Nov 12, 2026 |
| DFAX | 0.01% | 25,389 | $ 1.523M | Nov 12, 2026 |
| DEXC | 0.01% | 507 | $ 30.41K | Nov 12, 2026 |
| AVEM | 0.01% | 36,271 | $ 2.178M | Nov 16, 2026 |
| AVSE | 0.01% | 428 | $ 25.697K | Nov 16, 2026 |
| AVXC | 0.01% | 437 | $ 26.237K | Nov 16, 2026 |









(1).png)